Metformin Shows Surprising Protection Against Vision Loss in Diabetes Patients, Study Finds

A groundbreaking study from the University of Liverpool has uncovered a previously unknown benefit of metformin, a medication prescribed to millions of Americans with type 2 diabetes: it may dramatically reduce the risk of developing intermediate age-related macular degeneration (AMD), the leading cause of blindness in Western nations. In a five-year analysis of 2,000 diabetes patients over 55, researchers found that those taking metformin had a 37% lower likelihood of progressing to intermediate AMD compared to those not using the drug. The findings, published in *BMJ Open Ophthalmology*, mark the first time scientists have directly linked metformin to AMD protection using retinal imaging—a significant leap beyond earlier studies that relied on indirect data like insurance claims.

• Metformin users with diabetes were 37% less likely to develop intermediate AMD over five years compared to non-users.
• The study analyzed retinal scans from 2,000 participants in Liverpool’s diabetic eye screening program, the first to use direct imaging evidence.
• AMD affects 10-15% of people over 65 in high-income countries, costing the UK alone £11.1 billion annually.
• Geographic atrophy, a severe form of AMD, currently has no approved treatments in Europe or the UK.

Why AMD is a Looming Vision Crisis—and How Metformin May Help

Age-related macular degeneration is a degenerative eye disease that erodes central vision, the part of sight responsible for reading, driving, and recognizing faces. The disease manifests in two primary forms: 'dry' AMD, which involves gradual tissue deterioration, and 'wet' AMD, characterized by the growth of abnormal blood vessels that leak blood and fluid into the retina. While wet AMD can be treated with eye injections, dry AMD—particularly the advanced stage known as geographic atrophy—has no approved therapies in Europe or the UK, leaving patients with few options as their vision fades irreparably.

The Economic and Human Toll of AMD

The burden of AMD extends far beyond personal health. In the United Kingdom alone, the condition costs an estimated £11.1 billion annually in healthcare expenses, social care, and lost productivity. Globally, AMD is projected to affect over 288 million people by 2040, with prevalence rising alongside aging populations. For individuals, the disease often begins with subtle symptoms—blurred or distorted central vision—before progressing to severe vision loss. Without treatment, many patients face a future of dependency, requiring assistance with daily tasks as their eyesight deteriorates.

Metformin’s Unexpected Role in Eye Health

Metformin, a first-line therapy for type 2 diabetes, has long been celebrated for its ability to lower blood sugar levels and reduce cardiovascular risks. But its potential role in protecting against AMD was largely unexplored until now. Prior research on this link relied on indirect measures, such as analyzing diagnostic codes from general practitioners or insurance claims in the U.S., which could introduce bias or inaccuracies. The Liverpool study, however, took a more precise approach by examining retinal photographs from participants in the city’s diabetic eye screening program. Over five years, researchers tracked the progression of AMD in patients taking metformin versus those who were not, adjusting for variables like age, sex, and diabetes duration. The results were striking: metformin users had a significantly reduced risk of developing intermediate AMD, with an adjusted odds ratio of 0.63 (95% confidence interval: 0.43–0.92).

Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments. What we need to do now is test metformin as a treatment for AMD in a clinical trial. Metformin has the potential to save many people’s sight.

How the Study Was Conducted: A First-of-Its-Kind Analysis

The research team, led by Dr. Nicholas Beare, a consultant ophthalmologist at the University of Liverpool, analyzed retinal images from 2,000 participants aged 55 and older who had been diagnosed with diabetes. All participants were part of Liverpool’s routine diabetic eye screening program, which uses standardized imaging to monitor for diabetic retinopathy—a common diabetes complication that damages the retina’s blood vessels. By repurposing this existing data, the researchers were able to evaluate AMD progression with unprecedented accuracy. The study’s methodology included grading the severity of AMD in each retinal scan, categorizing patients into groups based on whether they were taking metformin at the time of imaging.

Beyond Diabetes: Metformin’s Expanding Medical Benefits

Metformin’s potential to combat AMD is just the latest in a series of discoveries highlighting its broader health benefits. Originally derived from the French lilac plant, metformin has been used to treat diabetes since the 1950s and is now one of the most prescribed medications worldwide. Beyond its glucose-lowering effects, studies have suggested that metformin may reduce the risk of certain cancers, including breast and prostate cancer, and slow cognitive decline in conditions like Alzheimer’s disease. Its anti-inflammatory and antioxidant properties are thought to play a role in these protective effects, though the exact mechanisms remain under investigation.

What’s Next for AMD Treatment? Clinical Trials and Beyond

While the Liverpool study provides compelling evidence, experts caution that more research is needed before metformin can be recommended as a standard treatment for AMD. The next critical step is a randomized clinical trial, where some participants would receive metformin specifically to assess its efficacy in slowing or reversing AMD progression. Such a trial would need to include a diverse population to ensure the findings are generalizable. Additionally, researchers are exploring whether metformin’s protective effects extend to the general population—those without diabetes—who may also be at risk for AMD.

Challenges in AMD Research and Treatment

The path to effective AMD treatments has been fraught with challenges. For geographic atrophy—the dry form of AMD—there are currently no approved therapies in Europe or the UK, leaving patients with no recourse as their vision deteriorates. Wet AMD, while treatable with anti-VEGF injections, requires frequent clinic visits, often monthly or bi-monthly, which can be burdensome for patients and strain healthcare systems. Newer therapies, such as gene therapy and stem cell treatments, are in development, but they remain years away from widespread use. In this context, metformin’s potential as a low-cost, widely available drug could represent a paradigm shift in AMD management.

The Broader Implications for Public Health

The discovery of metformin’s protective effects against AMD underscores the importance of repurposing existing medications—a strategy that can accelerate treatment breakthroughs while reducing costs. Given that metformin is already approved and prescribed to millions of patients, its potential use for AMD could streamline the path to regulatory approval. Public health experts also note that this finding highlights the need for integrated care models, where diabetes management and eye health are coordinated to prevent complications like AMD. For patients with diabetes, who are already at higher risk for eye diseases like diabetic retinopathy, metformin’s added benefit could significantly improve long-term outcomes.

Expert Reactions: Cautious Optimism Surrounds the Findings

The medical community has greeted the study with a mix of enthusiasm and caution. Dr. Emily Chew, director of the Division of Epidemiology and Clinical Applications at the National Eye Institute (NEI), called the findings "promising" but emphasized the need for further validation. "While observational studies like this provide valuable insights, they cannot establish causation," Chew said. "We need clinical trials to confirm whether metformin truly prevents AMD or merely correlates with its incidence." Other experts pointed out that metformin’s side effects, such as gastrointestinal discomfort, could limit its suitability for some patients. Nevertheless, the study has sparked renewed interest in exploring metformin’s therapeutic potential beyond diabetes.

What This Means for Patients and Healthcare Providers

For patients with diabetes, the news offers a glimmer of hope in managing two major health concerns: blood sugar levels and vision preservation. While metformin is not currently prescribed for AMD prevention, its dual role in diabetes and eye health could influence treatment decisions. Healthcare providers may now consider AMD risk when selecting diabetes medications, particularly for older adults. Patients, meanwhile, are encouraged to prioritize regular eye exams, as early detection of AMD remains the best defense against vision loss. The study also serves as a reminder of the importance of medication adherence—staying on prescribed metformin could provide an additional layer of protection against AMD.